This Week in Pediatrics — Jun 6, 2026

Welcome to This Week in Pediatrics. This week we're covering 10 notable papers spanning the care of extremely preterm infants, a re-evaluation of common and future therapeutics, and new approaches to assessing and preventing chronic conditions. Let's dive in.

We begin in the NICU, with a focus on our most vulnerable patients: the extremely preterm infant. A series of papers this week provides a comprehensive look from acute respiratory and cardiac management to long-term outcomes. First, in The Lancet Child & Adolescent Health, an exploratory analysis of the PLUSS trial details the arduous respiratory journeys of infants born before 26 weeks gestation [5]. The data paints a stark picture of prolonged support. For infants born at 22 to 23 weeks, 97% were intubated at birth, with a median time to first extubation of 15 days, and two-thirds of these infants required reintubation. Even for those born at 25 weeks, the median duration of mechanical ventilation for survivors was 12 days. By 40 weeks postmenstrual age, the vast majority of infants born at 22-23 weeks who were still in the hospital remained on oxygen or respiratory support. These data provide crucial prognostic information for counseling families. Complementing this, a review in Pediatric Research highlights the unique cardiovascular challenges in periviable neonates, arguing for a shift away from simple blood pressure targets [9]. The authors propose a phenotype-based approach to assessment, using tools like targeted neonatal echocardiography to distinguish between states like primary myocardial dysfunction, ductal physiology, and pulmonary hypertension. This allows for more tailored, physiology-based management rather than a one-size-fits-all approach to hypotension. But what about our early interventions? A multicenter randomized trial published in Pediatrics followed extremely low birthweight infants who received an additional gram per day of parenteral amino acids for the first five days of life [4]. At school age, there was no benefit. The intervention group showed no improvement in the primary outcome of survival free of neurocognitive impairment. Concerningly, they had lower muscle strength and may have had an increased risk of poor psychosocial functioning. This important negative trial suggests that more protein early on is not necessarily better and may even cause harm, challenging a common nutritional strategy. Looking further into the future, a single-arm trial in Pediatric Research offers a hopeful message about the long-term health of this population [10]. Young adults born very preterm who participated in a 14-week structured exercise program showed significant improvements in cardiovascular parameters like peak circulatory power. Notably, preterm participants who had elevated or hypertensive blood pressure at baseline experienced significant reductions in their 24-hour and awake blood pressures, an effect not seen in term-born controls. This suggests that the adverse cardiovascular programming from preterm birth is, at least in part, modifiable with lifestyle interventions in adulthood.

Next, we turn to therapeutics, with a new trial on a common treatment and a look at the future of drug development. For anyone managing infants on the wards in winter, a study in Acta Paediatrica is a must-read [7]. This multicenter, double-blind randomized controlled trial in Poland compared nebulized 3% hypertonic saline to 0.9% normal saline for infants hospitalized with mild-to-moderate bronchiolitis. The results were clear: hypertonic saline did not reduce the length of hospital stay or improve clinical severity scores. The median stay was virtually identical at around 2.7 days in both groups. While there were fewer readmissions in the hypertonic saline group, this was not the primary outcome. This trial adds strong evidence that this very common intervention offers no significant clinical benefit for shortening hospitalization. Looking toward potential future treatments, a preclinical study in Pediatric Research used an adaptive design in rodent models of neonatal hypoxia-ischemia to compare four repurposed drugs [2]. The study found that azithromycin and erythropoietin consistently provided superior neuroprotection compared to caffeine and melatonin. In models that included hypothermia, azithromycin or EPO were clear winners. The results support azithromycin as a promising candidate neuroprotective agent that warrants investigation in larger animal models of neonatal brain injury. Finally, a review article, also in Pediatric Research, provides a primer on the rapidly advancing field of cell and gene therapies [8]. With 14 such therapies already approved for pediatric use in the United States, it's a critical area for clinicians to understand. The review explains how these treatments defy traditional pharmacokinetic principles, instead relying on concepts like cellular kinetics, expansion, and persistence. Development and dosing depend heavily on preclinical models, which is especially crucial in rare pediatric diseases where large trials are not feasible.

Our final theme covers new approaches to chronic conditions, from assessment tools to long-term prevention. First, for the growing population of youth with post-acute infection syndromes and myalgic encephalomyelitis or chronic fatigue syndrome, or ME/CFS, the European Journal of Pediatrics introduces two new assessment tools [1]. The MCFC Activity Scale and Participation Scale are brief, age-adapted questionnaires designed for clinical use. A validation study in over 90 patients showed they have good internal consistency and correlate well with established measures of function and fatigue. They demonstrated good ability to discriminate between patients with and without an ME/CFS diagnosis, making them pragmatic screening and assessment tools for this vulnerable group. Next, Nature Reviews Disease Primers provides a comprehensive overview of atopic dermatitis, the most common inflammatory skin disease in childhood [3]. The primer summarizes the complex interplay between skin barrier dysfunction, immune pathways, and the microbiome. It also highlights the significant burden of comorbidities, including the atopic march to asthma and food allergies, as well as mental health disorders. The review charts the therapeutic evolution from broad immunosuppressants to highly targeted biologics and small molecules, while noting the global inequity in access to these newer agents. Lastly, a fascinating paper in Cell looks at the future of disease prevention, using lung cancer as a model [6]. Using machine learning, researchers identified a 14-protein plasma signature that can predict lung cancer risk more than five years before diagnosis. This signature was elevated in smokers and those exposed to particulate matter, and appears to reflect a pro-inflammatory state in the lungs. In the context of the CANTOS trial, which showed that an anti-inflammatory drug could reduce lung cancer incidence, this protein signature was able to identify individuals who benefited most from the therapy. While focused on adult oncology, the paper's principles of identifying risk based on inflammatory markers and environmental exposures have broad relevance for preventative medicine in pediatrics.

If you only have time for one paper this week, make it the long-term follow-up of early amino acid supplementation in ELBW infants from Pediatrics [4]. It's a methodologically strong study with a clear, practice-changing, and cautionary result: an intervention intended to help not only failed to improve long-term neurocognitive outcomes but may have caused harm to muscle strength. This underscores the critical importance of long-term follow-up for our most vulnerable neonatal patients.

Here are the key takeaways from this week in Pediatrics: First, for extremely low birthweight infants, providing an additional gram per day of parenteral amino acids for the first five days of life does not improve school-age neurocognitive outcomes and may be associated with reduced muscle strength. Second, for infants hospitalized with mild-to-moderate bronchiolitis, nebulized 3% hypertonic saline is no more effective than normal saline at reducing length of stay or improving clinical severity scores. Third, some long-term cardiovascular consequences of preterm birth appear to be modifiable. A structured exercise program in young adulthood can improve cardiac function and, notably, lower blood pressure in preterm-born individuals with hypertension. Fourth, for children and adolescents with post-viral syndromes or suspected ME/CFS, the new MCFC Activity and Participation Scales are validated, pragmatic tools that can aid in screening and clinical assessment. Finally, preclinical research has identified azithromycin as a promising neuroprotective agent in models of neonatal hypoxic-ischemic injury, warranting further study.

That's your roundup for This Week in Pediatrics. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.